Shenzhen Han's Pharmaceutical Co., Ltd. announces that its wholly-owned subsidiary, Han's Pharmaceutical (Wuhan) Co., Ltd., has received approval from the NMPA for its Liraglutide Active Pharmaceutical Ingredient (API) marketing application. This approval marks a significant milestone, positioning the company as the first in China to obtain approval for chemically synthesized Liraglutide. The company acknowledges potential sales risks post-launch.
Summary generated by AI · Always verify with source document
Securities Code: 300199
Securities Abbreviation: Han's Pharmaceutical
Announcement No.: 2026-044
Shenzhen Han's Pharmaceutical Co., Ltd.
Announcement on Approval of Marketing Application for Liraglutide API by Wholly-Owned Subsidiary
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.